Related Experiment Video

Updated: Jul 15, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

[Anti-TNFalpha treatment of juvenile uveitis]

Hans Callø Fledelius1, Susan M Nielsen, Kamilla Rothe Nissen

  • 1Rigshospitalet, Øjenafdelingen, København Ø.

Ugeskrift for Laeger
|April 18, 2007
PubMed

Insights

Anti-tumor necrosis factor alpha (TNFα) treatment effectively reduced uveitis activity in 11 children with juvenile idiopathic arthritis (JIA) and related conditions. Early intervention with anti-TNFα agents like infliximab may prevent long-term ocular complications.

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Context:

  • Juvenile idiopathic arthritis (JIA) frequently causes uveitis.
  • Severe uveitis requires aggressive treatment to prevent vision loss.
  • Conventional therapies may be insufficient for sight-threatening uveitis.

Purpose:

  • To evaluate the efficacy of anti-tumor necrosis factor alpha (anti-TNFα) therapy in pediatric patients with severe uveitis.
  • To assess treatment outcomes in patients with JIA-associated uveitis and Blau's syndrome.
  • To compare the effectiveness of infliximab and etanercept in managing uveitis.

Summary:

  • Eleven children with severe uveitis, including nine with JIA and two with Blau's syndrome, received anti-TNFα treatment.
  • All patients experienced reduced uveitis activity, with outcomes linked to visual acuity and decreased use of immunosuppressants.
  • Infliximab demonstrated superiority over etanercept in treating uveitis.

Impact:

  • Anti-TNFα therapy is effective in managing severe uveitis associated with JIA and other inflammatory conditions.
  • Early initiation of anti-TNFα treatment can prevent long-term ocular complications and preserve vision.
  • Findings support early use of anti-TNFα agents for active uveitis unresponsive to standard treatments.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...